Introduction
Left ventricular hypertrophy (LVH) is prevalent and associated with a poor long-term prognosis. The Framingham Heart Study, for example, showed that LVH was present in 15-20% of adults, and that, for each 50 g/m 2 increment of left ventricular mass, the relative risk of cardiovascular death increased by 1.73 in men and 2.12 in women. 1 Although hypertension, obesity and valvulopathies account for most causes of LVH, it is important to investigate patients with otherwise unexplained LVH since many causes are treatable.
Practical approach to the evaluation of left ventricular hypertrophy
Although several electrocardiographic (ECG) criteria for the identification of LVH are available, additional investigations [notably transthoracic echocardiography (echo)] are invariably required due to the lack of sensitivity and specificity of ECG. The European Association of Echocardiography definition of LVH includes the demonstration of interventricular septal and/or posterior wall thickness in end-diastole ≥13 mm. 2 Echocardiography can additionally interrogate valve function and characterize LVH as concentric (uniform mechanism, e.g. LV pressure overload, myocardial infiltration), or eccentric [e.g. asymmetrical septal hypertrophy in hypertrophic cardiomyopathy (HCM)]. After the identification of LVH, a practical approach to its further assessment includes a clinical review with targeted investigations aimed firstly to exclude common causes; e.g. hypertension, obesity and valve disease. Thereafter, evaluation involves a systematic approach to exclude less common causes, e.g. hypertrophic and other cardiomyopathies, myocardial infiltration, metabolic disorders, and syndromic conditions associated with LVH. Table 1 provides a systematic scheme incorporating clinical pearls and diagnostic pointers to help target adjunctive investigations and help identify the aetiology of LVH. Disorders causing or associated with LVH are arranged in a pathological hierarchical manner with common conditions appearing first, followed by rarities.
Many heart muscle disorders presenting with LVH are due to inherited mutations in genes encoding contractile proteins of the cardiac sarcomere, metabolic pathways, or mitochondrial proteins. 3 Hypertrophic cardiomyopathy is the commonest inherited cardiac condition and an important cause of (potentially preventable) sudden arrhythmic death. As such, it is placed high in the systematic scheme of LVH (Table 1 ) and should be considered early in the diagnostic work-up of unexplained LVH.
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy has been defined as a hypertrophied, non-dilated LV in the absence of another systemic or cardiac process capable of producing LVH. 3, 4 Hypertrophic cardiomyopathy is the most common genetically determined cardiomyopathy with an estimated clinical prevalence in the population of 1:500. 4 In most cases, HCM is autosomal dominantly transmitted through mutations in one of several cardiac sarcomeric genes. 3 Recent progresses in molecular genetics have generated interest in adopting a genetics-based HCM classification. 4 However, the European classification of hypertrophic, dilated, arrhythmogenic right ventricular, restrictive nonhypertrophied, and unclassified forms of cardiomyopathy based on clinical, haemodynamic, and structural features may be more practical. 5 This is particularly relevant since in many cases genotypephenotype correlations remain elusive. Although criteria for the diagnosis of HCM are described, 3 several secondary forms of concentric LVH exist. A screening study among 508 'HCM' patients, for example, found that 1% 
Fabry disease
Fabry disease is an X-chromosome-linked disease of lysosomal metabolism resulting in attenuated activity or, in most males, absence of the enzyme a-galactosidase A (a-Gal A). 7 As a result, the breakdown of glycosphingolipids is impaired leading to systemic lysosomal accumulation of globotriaosylceramide (Gb 3 ). It is estimated that 1 in 40 000 males has Fabry disease, whereas the estimated prevalence in the general population is 1 in 117 000. 7 Unlike many sex-linked disorders, the condition can affect both genders although its course is often less pronounced in women. 8 Genetic screening following diagnosis of a new index case can lead to the identification of additional family members with the Fabry gene. 9 Most families have 'private' mutations found only in that family and the wide range of known mutations (hundreds of different mutations have been identified) 8 may contribute to the variations in the residual enzyme activity and clinical presentation of Fabry disease. Multi-system morbidity commonly develops in childhood ( Figure 1 ) and, with progression of the disease, life-threatening complications often occur in adulthood.
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Gender differences in Fabry disease
The phenomenon of X-chromosome inactivation (i.e. permanent epigenetical silencing of one X-chromosome creating cellular mosaicism in females) may partly account for the disease presentation in females. 8 Thus, although female Fabry patients may develop increased myocardial mass and LVH, the presentation of this manifestation is usually delayed by 10 years in comparison with male Fabry counterparts. In addition, while myocardial fibrotic scars (detectable by late enhancement imaging) are common in both genders with Fabry disease, scarring has been observed even in the non-hypertrophied stages of the disease in female patients. 13 Another important difference is that Fabry women are more likely than men to develop a cardiac variant characterized by isolated cardiac involvement only. Therefore, the threshold for offering gene testing in females suspected of Fabry disease should be low.
Cardiac manifestations of Fabry disease
Globotriaosylceramide accumulation Globotriaosylceramide accumulation has been observed in vascular endothelial and smooth muscle cells, cardiomyocytes, conduction tissue and valvular fibroblasts. 7 Although incompletely described, it is likely that inflammatory and neuro-hormonal mechanisms are involved in subsequent cellular and vascular dysfunction, leading to tissue ischaemia, hypertrophy, and fibrosis.
Left ventricular hypertrophy
Left ventricular hypertrophy is a key feature in Fabry disease and is reported in up to 50% of males and one-third of females. 10 Conversely, among individuals with uncharacterized LVH, the Fabry gene has been identified in up to 4% of cases. 14 In most cases the LVH is concentric; however, an asymmetrical variety with septal thickening and posterior wall fibrotic thinning may present in severe cases (Figure 2A) . Right ventricular hypertrophy is also common and may progress to right ventricular dilation.
Myocardial fibrosis
The fibrotic process in Fabry cardiomyopathy starts with intramural involvement with later transmural involvement. Fibrosis is Left ventricular hypertrophy in Fabry disease invariably present in the basal posterolateral segments. 15 Cardiac magnetic resonance (CMR) is the imaging modality of choice in these cases ( Figure 2B ).
Conduction abnormalities and arrhythmias
Typical ECG findings include P -R interval shortening due to shortening of the P-wave duration. Later abnormalities include P -R interval prolongation, voltage signs of LVH, repolarization abnormalities, and atrio-ventricular block. Longitudinal studies suggest that arrhythmias occur in 27-42% of male and 27% of female patients with Fabry disease. 11, 16 Management of arrhythmias (including device therapies) should follow standard guidelines. 15 
Vascular abnormalities
Involvement of the coronary microcirculation can lead to angina (13 -23% of patients), but myocardial infarction is uncommon (2% of patients). 11, 16 Arterial hypertension may result from renal insufficiency.
Extra-cardiac features of Fabry disease
Childhood symptoms (Figure 1) typically present between the ages of 5 and 10 years. Symptoms include: (i) small fibre neuropathic pain, chronic burning pain in hands and feet, recurrent severe limb pain triggered by fever, stress, physical activity or altered temperature, postprandial abdominal cramping, and diarrhoea, (ii) lack of sweating (hypohidrosis), (iii) thermal perception deficits with heat and exercise intolerance, (iv) whorl-like bilateral corneal opacities not affecting visual acuity (cornea verticillata, Figure 1 ; left panel), (v) small reddish/purple vascular lesions on the buttocks, groin, umbilicus, and upper thighs (angiokeratomata, Figure 1 ; right panel). 7 Microalbuminuria may develop in young patients and is an antecedent to progressive Fabry nephropathy. Overt proteinuria and progressive decline in the glomerular filtration rate appear by the age of 20 -30 years. 7, 11 Affected males typically progress to kidney failure by the fourth decade of life. Early stroke (ischaemic or haemorrhagic) has been reported in 6.9% of untreated males and 4.3% of females, occurring before the age of 30 years in one-fifth of the patients.
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Diagnostic algorithm for Fabry disease
We propose a practical diagnostic approach to assist clinicians encountering undiagnosed Fabry patients presenting with LVH ( Figure 3) . After excluding common causes of LVH ( Table 1) and faced with unexplained LVH, a stepwise approach is suggested. First, the medical history is explored focusing on characteristic complications of Fabry disease. Red flags pointing towards a diagnosis of Fabry disease include the typical childhood symptoms described above, a family history of cardiomyopathy, chronic kidney disease, stroke, unexplained early death, or other signs/ symptoms of Fabry disease. The absence of male-to-male transmission in the pedigree of a family burdened by LVH is a key feature of this X-linked disorder.
Physical examination may provide additional clues to Fabry disease, although in some cases multi-organ involvement may be absent. Angiokeratomata (Figure 1 ; right panel) and cornea verticillata ( Figure 1 ; left panel) are typical clinical signs. Urine dipstick may reveal proteinuria, while the ECG may identify a short P -R interval.
Where Fabry disease is suspected, an a-Gal A enzyme activity assay in plasma or peripheral leucocytes should be performed. 7, 9 Most males completely lack lysosomal a-Gal A enzyme activity; however, a low level of residual a-Gal A (1-10% of normal) may be found in males with a late-onset cardiac phenotype. 7 Interpretation of the enzyme assay in females is difficult since enzyme activity may be low normal or normal in up to one-third of the females with Fabry disease. Therefore, suspected female Fabry patients should undergo gene analysis as a first line test. 7, 9 More recently, a dried blood spot enzyme assay has been introduced as a first-tier screening test for Fabry disease. 9 The test involves placing whole blood droplets on absorbent filter paper with the advantage that samples can be stored for some weeks before posting to a central laboratory for batch testing. Given the availability of an accurate diagnostic enzyme assay, cardiac biopsy is not generally required for diagnosing Fabry disease. The observation of cardiac cellular Gb 3 accumulation in patients undergoing cardiac biopsy during investigations for Once the Fabry mutation has been identified in an index patient, targeted mutation analysis can be used to diagnose at-risk males and females in that specific family. Genetically proven Fabry patients without phenotypic manifestations should undergo annual clinical follow-up. Information on genotype-phenotype correlations in Fabry disease is limited and, therefore, the decision to initiate enzyme replacement therapy (ERT) should be guided by the evaluation of signs, symptoms, and organ involvement.
Enzyme replacement therapy
The importance of recognizing Fabry disease lies in the availability of disease-modifying ERT. Two ERTs are currently available for Fabry disease; agalsidase alfa and agalsidase beta, both administered intravenously every other week. Prospective clinical trials have demonstrated that ERT can reduce the risk of major clinical events, remodel the LV, improve cardiac function, and increase exercise tolerance. 9, 19, 20 Extra-cardiac benefits include; stabilization of renal function and improvement of peripheral pain. In addition, serial histological analyses of vascular endothelial cells in patients receiving ERT demonstrate that treatment is associated with intra-cellular Gb 3 clearance. 19 It has become increasingly clear that the severity of baseline hypertrophy and fibrosis determines the cardiac outcome with ERT, and that the best treatment outcomes can be obtained when treatment is started early. 20 Once established, tissue and organ damage cannot be reversed. Thus, stabilization of the existing pathology, or slowing the progression to serious cardiac complications and improving survival, may be the most optimal outcome. Therefore, early diagnosis and screening relatives of confirmed cases are essential. Optimal care thus involves cascade screening and regular follow-up involving disease-specific and supportive treatments that are best served in the context of a multidisciplinary team.
Conclusions
Left ventricular hypertrophy remains a common pathology which requires exhaustive characterization. In most cases, LVH may be attributable to hypertension, valve disease, or obesity. It is important, however, not to miss potentially treatable conditions such as Fabry disease. Fabry disease is a progressive, multi-organ, genetic disease affecting both genders. Cardiac manifestations, including LVH and arrhythmias, are common and the cardiac complications are a key cause of premature death. We have proposed a practical approach to facilitate the identification of patients with otherwise unexplained LVH and Fabry disease. Confirmation of Fabry disease involves an enzyme activity assay in males and genetic testing in females. Once the mutation is known, extended family screening is important to identify unaffected relatives who may have the most to gain from ERT.
